Rates of Progression to Tau‐PET Positivity in Preclinical Alzheimer’s Disease

Abstract

Background: Previous work from our group has shown that tau‐PET positivity—defined using an FDA/EMA‐approved visual interpretation method reflecting Braak stages V–VI—marks a key milestone closely associated with the onset of clinical symptoms in preclinical Alzheimer’s disease (AD).